More Genetic Clues Needed to Improve Lung Cancer Treatment
David Spigel, a lung cancer specialist, explains the potential of biomarkers in the search for new treatments.
David Spigel, director of the Lung Cancer Research Program at Sarah Cannon Research Institute in Nashville, answers CURE's questions on how biomarkers will affect lung cancer treatment now and in the future.
Podcast: David Spigel and the future of lung cancer biomarkers
While only a fraction of lung cancer mutations have a treatment that targets them, Spigel expects that in the near future, many more genetic clues will be uncovered. These discoveries will help shape treatment decisions for a wider range of patients.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Listen
